Milestone Pharmaceuticals (MIST) Cash from Investing Activities (2018 - 2026)

Milestone Pharmaceuticals (MIST) has 9 years of Cash from Investing Activities data on file, last reported at -$80.0 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 338.31% year-over-year to -$80.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.4 million (down 248.62% YoY) and the FY2025 annual result came in at $11.2 million, up 35.77% from the prior year.
• Cash from Investing Activities declined to -$80.0 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $33.6 million in Q1 2025 to a low of -$80.0 million in Q1 2026.
• A 5-year average of -$6.6 million and a median of -$8.0 million in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 474.6% — and 2025, when it sank 639.79%.
• Tracing MIST's Cash from Investing Activities over 5 years: stood at -$17.0 million in 2022, then soared by 180.38% to $13.7 million in 2023, then soared by 41.37% to $19.3 million in 2024, then slumped by 86.02% to $2.7 million in 2025, then slumped by 3060.78% to -$80.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$80.0 million (Q1 2026), $2.7 million (Q4 2025), and -$35.0 million (Q3 2025), per Business Quant data.